<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04249427</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00104284</org_study_id>
    <nct_id>NCT04249427</nct_id>
  </id_info>
  <brief_title>Erenumab for Idiosyncratic Facial Pain</brief_title>
  <official_title>A Randomized, Double-Blinded, Single Site Study to Evaluate the Efficacy of Erenumab for Treatment of Idiosyncratic Facial Pain Mimicking Rhinosinusitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Jang, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase IV randomized, double-blinded, placebo-controlled study to evaluate the&#xD;
      efficacy of Erenumab in subjects with midfacial pain or pressure, without clinical or&#xD;
      radiographic evidence of sinusitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible participants are randomized to receive either Erenumab or placebo by subcutaneous&#xD;
      injection once monthly for 6 months. Study duration is eight months which includes a 30 day&#xD;
      screening/lead-in period and 6 monthly treatment visits followed by a follow-up visit one&#xD;
      month following the last dose of study drug administration. Participants will be expected to&#xD;
      score on a scale of 1 to 10 their symptoms of facial pain/pressure, nasal congestion, and&#xD;
      rhinorrhea as well well as any rescue medicines taken for pain each day via a mobile app.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean number of days per month with significant mid-facial pain or pressure</measure>
    <time_frame>Baseline, 1,3, and 6 months</time_frame>
    <description>change in number of days per month with significant mid-facial pain or pressure (defined as greater than 4/10 on scale of 1 - 10) measured by daily dairy completion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in SNOT-22</measure>
    <time_frame>Baseline, 1, 3 and 6 months</time_frame>
    <description>Measured by SNOT-22 survey completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Function</measure>
    <time_frame>Baseline, 1, 3 and 6 months</time_frame>
    <description>Measured by Migraine Function Impact Questionnaire (MFIQ) survey completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Usual Activities</measure>
    <time_frame>Baseline, 1, 3 and 6 months</time_frame>
    <description>Measured by Migraine Functional Impact Questionnaire (MFIQ) survey completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Social Function</measure>
    <time_frame>Baseline, 1, 3 and 6 months</time_frame>
    <description>Measured by Migraine Functional Impact Questionnaire (MFIQ) survey completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Emotional Function</measure>
    <time_frame>Baseline, 1, 3 and 6 months</time_frame>
    <description>Measured by Migraine Functional Impact Questionnaire (MFIQ) survey completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Overall Impact (global)</measure>
    <time_frame>Baseline, 1, 3 and 6 months</time_frame>
    <description>Measured by Migraine Functional Impact Questionnaire (MFIQ) survey completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in average number of days per month with significant nasal congestion</measure>
    <time_frame>Baseline, 1, 3 and 6 months</time_frame>
    <description>Measured by daily diary completion via mobile app</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in average number of days per month with significant rhinorrhea</measure>
    <time_frame>Baseline, 1, 3 and 6 months</time_frame>
    <description>Measured by daily diary completion via mobile app</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in doses of rescue pain medications</measure>
    <time_frame>Baseline, 1, 3 and 6 months</time_frame>
    <description>Measured by daily diary completion via mobile app</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean daily pain score</measure>
    <time_frame>Baseline, 1, 3 and 6 months</time_frame>
    <description>Measured by daily diary completion via mobile app</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Facial Pain</condition>
  <condition>Rhinosinusitis</condition>
  <arm_group>
    <arm_group_label>Erenumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>140mg Erenumab administered by subcutaneous injection (in the abdomen, thigh, or upper arm), once monthly for six months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered by subcutaneous injection (in the abdomen, thigh, or upper arm), once monthly for six months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erenumab Prefilled Syringe</intervention_name>
    <description>140mg Erenumab, pre-filled syringe given by subcutaneous injection</description>
    <arm_group_label>Erenumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, pre-filled syringe given by subcutaneous injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults 18 years of age and older presenting to Duke Head &amp; Neck Surgery and&#xD;
             Communications Sciences clinic for evaluation of rhinosinusitis and/or facial pain or&#xD;
             pressure.&#xD;
&#xD;
          2. Symptoms are present at least 10 days a month for the last 3 months as reported by&#xD;
             subject.&#xD;
&#xD;
          3. Symptoms must include midfacial pain or uncomfortable pressure (may be unilateral or&#xD;
             bilateral), which is defined as pain in the regions overlying the maxillary, ethmoid,&#xD;
             frontal sinuses either together or individually.&#xD;
&#xD;
          4. Nasal endoscopy in the last three months shows no signs of inflammation (i.e. thick&#xD;
             drainage, polyps, watery edema in the middle meatus or spheno-ethmoid recess (mild&#xD;
             edema permitted).&#xD;
&#xD;
          5. Sinus CT scan or MRI within 12 months of enrollment during a symptomatic period shows&#xD;
             no more than scattered minimal mucosal edema or mucous retention cyst with patent&#xD;
             infundibula bilaterally. For subjects with a CT scan more than 12 months old or just&#xD;
             an MRI, a CT will be repeated for study purposes. For patients with CT scans less than&#xD;
             12 months old, a CT will be repeated for study purposes if the subject has changes in&#xD;
             symptoms suggestive of sinusitis.&#xD;
&#xD;
          6. Ability to read/write English.&#xD;
&#xD;
          7. Has a smart phone, ipod or iPad touch for completion of the EMA on a daily basis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypersensitivity to erenumab or to any of the drug components (acetate, polysorbate,&#xD;
             and sucrose).&#xD;
&#xD;
          2. Previous exposure to erenumab or any other CGRP inhibitor in the six months prior to&#xD;
             treatment.&#xD;
&#xD;
          3. Allergy to latex.&#xD;
&#xD;
          4. Inability to differentiate facial pain from other headaches.&#xD;
&#xD;
          5. Non-English speaking or unable to provide written informed consent.&#xD;
&#xD;
          6. On a preventative migraine medication (see below) during the 30 day lead-in period:&#xD;
&#xD;
               -  Category 1: Divalproex sodium, sodium valproate&#xD;
&#xD;
               -  Category 2: Topiramate&#xD;
&#xD;
               -  Category 3: Beta blockers (for example: atenolol, bisoprolol, metoprolol,&#xD;
                  nadolol, ebivolol, pindolol, propranolol, timolol)&#xD;
&#xD;
               -  Category 4: Tricyclic antidepressants (for example: amitriptyline, nortriptyline,&#xD;
                  protriptyline)&#xD;
&#xD;
               -  Category 5: Serotonin-norepinephrine reuptake inhibitors (for example:&#xD;
                  venlafaxine, desvenlafaxine, duloxetine, milnacipran)&#xD;
&#xD;
               -  Category 6: Flunarizine, verapamil&#xD;
&#xD;
               -  Category 7: Lisinopril, candesartan&#xD;
&#xD;
          7. Received botulinum toxin (Botox) to the head and neck for migraines in the last four&#xD;
             months.&#xD;
&#xD;
          8. More than one major surgery of the nose or sinuses. Endoscopic sinus surgery,&#xD;
             septoplasty, rhinoplasty, and turbinate surgery are not considered major surgery.&#xD;
&#xD;
          9. History of uncontrolled or unstable blood pressure.&#xD;
&#xD;
         10. History of liver failure.&#xD;
&#xD;
         11. History of malignancy in the last five years except non-melanoma skin cancers,&#xD;
             cervical or breast ductal carcinoma in situ.&#xD;
&#xD;
         12. Active seizure disorder or other significant neurological conditions other than&#xD;
             migraine.&#xD;
&#xD;
         13. Myocardial infarction (MI), stroke, transient ischemic attack (TIA), unstable angina,&#xD;
             or coronary artery bypass surgery or other revascularization procedure within 12&#xD;
             months prior to screening.&#xD;
&#xD;
         14. History or evidence of any other unstable or clinically significant medical condition&#xD;
             that in the opinion of the sponsor-investigator/ Principal Investigator, would pose a&#xD;
             risk to subject safety or interfere with the study evaluation, procedures or&#xD;
             completion.&#xD;
&#xD;
         15. Evidence of drug or alcohol abuse or dependence within 12 months prior to screening,&#xD;
             based on medical records or patient self-report.&#xD;
&#xD;
         16. Pregnant or breastfeeding, or expecting to conceive during the study, including&#xD;
             through 16 weeks after the last dose of investigational product or placebo&#xD;
&#xD;
         17. Female subject of childbearing potential who is unwilling to use an acceptable method&#xD;
             of effective contraception during treatment with investigational product or placebo&#xD;
             through 16 weeks after the last dose of investigational product. Female subjects not&#xD;
             of childbearing potential are defined as any female who is post-menopausal by history,&#xD;
             defined as:&#xD;
&#xD;
               -  Age â‰¥ 55 years with cessation of menses for 12 or more months, OR&#xD;
&#xD;
               -  Age &lt; 55 years but no spontaneous menses for at least 2 years, OR&#xD;
&#xD;
               -  Underwent bilateral oophorectomy, bilateral salpingectomy, or hysterectomy&#xD;
&#xD;
         18. Unlikely to be able to complete all protocol required study visits or procedures.&#xD;
&#xD;
         19. Currently receiving treatment in another investigational device or drug study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Jang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Victoria Johnson</last_name>
    <phone>919-681-4595</phone>
    <email>vaj5@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy Walker</last_name>
    <phone>919-684-1732</phone>
    <email>amy.walker1@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University Medical Center and affiliated practices</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Jang, MD</last_name>
      <phone>919-681-7798</phone>
      <email>david.jang@duke.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 29, 2020</study_first_submitted>
  <study_first_submitted_qc>January 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2020</study_first_posted>
  <last_update_submitted>July 4, 2021</last_update_submitted>
  <last_update_submitted_qc>July 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>David Jang, M.D.</investigator_full_name>
    <investigator_title>Associate Professor of Head and Neck Surgery and Communication Sciences</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Facies</mesh_term>
    <mesh_term>Facial Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erenumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

